pSivida Corp. (NASDAQ:PSDV) – Analysts at B. Riley issued their Q2 2018 earnings per share (EPS) estimates for pSivida in a report released on Monday. B. Riley analyst A. D’silva forecasts that the company will earn ($0.14) per share for the quarter. B. Riley has a “Buy” rating and a $5.00 price target on the stock. B. Riley also issued estimates for pSivida’s Q3 2018 earnings at ($0.15) EPS, Q4 2018 earnings at ($0.13) EPS, FY2018 earnings at ($0.56) EPS, FY2019 earnings at ($0.49) EPS, FY2020 earnings at ($0.31) EPS, FY2021 earnings at ($0.14) EPS and FY2022 earnings at $0.00 EPS.
pSivida (NASDAQ:PSDV) last issued its quarterly earnings data on Tuesday, November 7th. The company reported ($0.15) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.15). pSivida had a negative return on equity of 139.56% and a negative net margin of 226.31%. The company had revenue of $0.39 million during the quarter, compared to analysts’ expectations of $0.74 million.
PSDV has been the topic of several other research reports. HC Wainwright set a $5.00 target price on pSivida and gave the company a “buy” rating in a report on Wednesday, October 11th. ValuEngine downgraded pSivida from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Laidlaw assumed coverage on pSivida in a research report on Wednesday, November 8th. They set a “buy” rating and a $5.00 target price on the stock. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $7.57.
Shares of pSivida (NASDAQ PSDV) traded down $0.03 during mid-day trading on Wednesday, reaching $1.24. The company had a trading volume of 373,700 shares, compared to its average volume of 503,005. pSivida has a 52-week low of $1.03 and a 52-week high of $2.45.
A hedge fund recently raised its stake in pSivida stock. Renaissance Technologies LLC grew its position in shares of pSivida Corp. (NASDAQ:PSDV) by 6.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 963,043 shares of the company’s stock after purchasing an additional 56,043 shares during the quarter. Renaissance Technologies LLC owned 2.82% of pSivida worth $1,656,000 as of its most recent filing with the SEC. 9.70% of the stock is currently owned by institutional investors.
WARNING: This piece was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.thelincolnianonline.com/2017/12/07/b-riley-comments-on-psivida-corp-s-q2-2018-earnings-psdv.html.
pSivida Company Profile
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with MarketBeat.com's FREE daily email newsletter.